Contrasting Low and High-Resolution Features for HER2 Scoring using Deep Learning

Ekansh Chauhan, Anila Sharma, Amit Sharma, Vikas Nishadham, Asha Ghughtyal, Ankur Kumar, Gurudutt Gupta, Anurag Mehta, C.V. Jawahar, P.K. Vinod · 2025

Read Contrasting Low and High-Resolution Features for HER2 Scoring using Deep Learning by Ekansh Chauhan, Anila Sharma, Amit Sharma, Vikas Nishadham, Asha Ghughtyal, Ankur Kumar, Gurudutt Gupta, Anurag Mehta, C.V. Jawahar, P.K. Vinod (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2503-22069.txt.

Introduction

Ekansh Chauhan and co-authors present a 2025 deep learning study on scoring HER2 in breast cancer slides. HER2 is a marker that helps sort breast cancer types and pick care. Pathologists now grade stained slides by eye, which is slow and varies between readers.

The team built a data set of 1,272 stained slides from India, covering HER2 and two hormone markers. They test models that read both low and high detail views of a slide. Their task is a three-way HER2 call: zero, low, or high. A ConvNeXt network that reads the whole slide did well in their tests. Such tools could ease the load on pathology labs.

Catalog record

CREATOREkansh Chauhan, Anila Sharma, Amit Sharma, Vikas Nishadham, Asha Ghughtyal, Ankur Kumar, Gurudutt Gupta, Anurag Mehta, C.V. Jawahar, P.K. Vinod
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2503-22069

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Contrasting Low and High-Resolution Features for HER2 Scoring using Deep Learning Ekansh Chauhan, Anila Sharma, Amit Sharma, Vikas Nishadham, Asha Ghughtyal, Ankur Kumar, Gurudutt Gupta, Anurag Mehta, C.V. Jawahar, P.K. Vinod Abstract Breast cancer, the most common malignancy among women, requires precise detection and classification for effective treatment. Immunohistochemistry (IHC) biomarkers like HER2, ER, and PR are critical for identifying breast cancer subtypes. However, traditional IHC classification relies on pathologists’ expertise, making it labor-intensive and subject to significant inter-observer variability. To address these challenges, this study introduces the India Pathology Breast Cancer Dataset (IPD-Breast), comprising of 1,272 IHC slides (HER2, ER, and PR) aimed at automating receptor status classification. The primary focus is on developing predictive models for HER2 3-way classification (0, Low, High) to enhance prognosis. Evaluation of multiple deep learning models revealed that an end-to-end ConvNeXt network utilizing low-resolution IHC images achieved an AUC, F1, and accuracy of 91.79%, 83.52%, and 83.56%, respectively, for 3-way classification, outperforming patch-based methods by over 5.35% in F1 score. This study highlights the potential of simple yet effective deep learning techniques to significantly improve accuracy and reproducibility in breast cancer classification, supporting their integration into clinical workflows for better patient outcomes. Journal: Journal of Pathology Informatics † † highlights: A breast cancer dataset specific to India (IPD-Breast), was developed to classify HER2, ER, and PR scores from IHC breast cancer slides, addressing a critical gap in computational pathology. A comprehensive analysis of various approaches for HER2 scoring was performed, including Multiple Instance Learning (MIL), end-to-end CNN-based slide-level classifiers, and patch-level classification pipelines. The impact of varying magnification levels on the performance of classification methods was evaluated. Deep learning-based HER2 3-way classification (0, Low, High) using low-resolution whole slide images is proposed, achieving an accuracy of 83.56%. 1 Introduction Breast cancer is a prevalent malignancy that originates from breast cells and can spread if not detected early. It is influenced by genetic, environmental, and lifestyle factors. Early detection through mammography, clinical exams, and advances in histopathological analysis is crucial for better prognosis and survival. Genetic mutations lead to uncontrolled cell growth and tumor formation, with tumors categorized by hormone receptor status, which influences treatment options. Higher incidence rates in developed countries are due to better detection methods, while higher mortality in developing countries is due to limited access to early detection and treatment [ 1 ] . Immunohistochemistry (IHC) biomarkers like HER2, ER, and PR play a critical role in diagnosis, prognosis, and treatment planning. These biomarkers are essential for personalized therapy, especially for triple-negative breast cancer patients. HER2 is overexpressed in 15-30% of breast cancers, leading to aggressive growth, with status determined by IHC and in situ hybridization [ 2 ] . ER and PR receptors, found in 70-80% of breast cancers, guide hormone therapy treatments [ 3 ] . The clinical significance of these biomarkers is summarized in Table 1 . Biomarker Clinical Significance HER2 0 or 1+ HER2-negative, no significant or low overexpression of HER2 protein HER2 2+ Equivocal, borderline overexpression; further testing is needed to establish Her2-negative or positive HER2 3+ HER2-positive, significant overexpression/amplification of HER2 protein ER/PR Positive Less aggressive, better prognosis, responsive to hormone therapies ER/PR Negative More aggressive, poorer prognosis, not responsive to hormone therapies Table 1 : Clinical Significance of HER2, ER, and PR Status Classification schemes for HER2 status in breast cancer, as illustrated in Table 2 , can be divided into binary, 3-way, and 4-way systems. The binary classification scheme, traditionally used to determine eligibility for HER2-targeted therapies, divides cases into HER2-negative (scores of 0, 1+, and 2+ without ISH amplification) and HER2-positive (scores of 2+ with ISH amplification and 3+) [ 4 ] . The 3-way classification scheme, gaining prominence due to recent clinical findings from the DESTINY-Breast04 trial, categorizes HER2 status into three groups: 0, Low (IHC 1+ and 2+ without ISH amplification), and High (IHC 3+ or 2+ with ISH amplification) [ 5 , 6 ] . This scheme recognizes the therapeutic potential for patients with low HER2 expression, who may benefit from new treatments like trastuzumab-deruxtecan [ 7 ] . The 4-way classification scheme, most commonly used, further refines these categories by distinguishing between HER2 0, 1+, 2+, and 3+. The 3-way classification scheme offers significant benefits over other schemes by simplifying the categorization process, making clinical decision-making efficient, and potentially reducing reliance on ISH when the primary goal is to distinguish between low and high HER2 expression for therapeutic decisions. Task HER2 Category 0 1+ 2+ (ISH -) 2+ (ISH +) 3+ Binary Negative ✓ ✓ ✓ Positive ✓ ✓ 3-Way 0 ✓ Low ✓ ✓ High ✓ ✓ 4-Way 0 ✓ 1+ ✓ 2+ ✓ ✓ 3+ ✓ Table 2 : HER2 Classification for Different Tasks. ISH refers to In Situ Hybridization. A significant challenge in breast cancer research is the scarcity of well-annotated datasets that capture the genetic, environmental, and lifestyle diversity of non-Western populations. While most existing datasets are derived from Western cohorts [ 8 ] , which have contributed to the development of computational models and diagnostic tools, there is still a need for region-specific data, particularly from Asia, to ensure the broader applicability and effectiveness of these models in diverse populations. This lack of region-specific data can limit the development of more effective diagnostic and treatment approaches. Compounding this issue is the complexity of IHC subtype classification, which relies on labor-intensive visual slide assessments prone to inter-observer variability and reproducibility issues. The inherent heterogeneity of tumor tissues, with varying levels of marker expression, further complicates accurate classification. Krishnamurthy el al. reported that a mean interobserver variability of 72.4% among pathologists across all HER2 scores [ 9 ] . These challenges underscore the critical need for comprehensive, pixel-level annotated datasets, as well as automated, objective, and reproducible computational methods to support pathologists in achieving precise subtype classification. Machine learning offers significant potential for IHC subtype classification in breast cancer histopathology, specifically for HER2 scoring, which involves classifying patches from whole slide images (WSIs) to predict the HER2 status of the entire slide. Most existing studies rely on patch-level labels, membrane segmentation, or manual region of interest (ROI) selection, which are labor-intensive and challenging to scale. Saha et al. proposed a deep learning framework for semantic segmentation and classification of cell membranes and nuclei to assist in HER2 scoring [ 10 ] . Cordeiro et al. introduced a method that bypasses segmentation and manual ROI selection, focusing on classifying HER2 scores into four or five categories [ 11 ] . Kabakıcı et al. proposed a method based on color deconvolution and hybrid multi-level thresholding for segmenting nuclei and boundaries, relying on expert-chosen regions of interest [ 12 ] . Wu et el. showed that distinguishing HER2 IHC scores of 0 and 1+ is particularly challenging due to HER2 heterogeneity and observer variability, highlighting a significant disadvantage of manual scoring methods [ 13 ] . Tewary et al. introduced AutoIHCNet for HER2 scoring on manually vetted ROIs, with limited patient data [ 14 ] . A recent study employed DenseNet and ViT models, utilizing small datasets and patch-level annotations [ 15 ] . These methods, while foundational, often involve extensive manual efforts and limited scalability due

Read the complete text